ÉúÎïͨ¡°ºËÐÄ¿¯ÎÀ¸Ä¿´´°ìÓÚ2002Ä꣬Ö÷Ö¼ÔÚÓÚÏò¹úÄÚרҵÈËʿչʾ¿ÆÑкËÐÄ¿¯ÎÒÔ¼°ÉúÃü¿ÆÑ§ÁìÓòÔÓ־ÿÆÚÖØµãÄÚÈÝ£¬Îª¶ÁÕß³ÊÏÖ¾«²Ê·×³ÊµÄ¹úÄÚ¿ÆÑж¯Ïò£¬ºÍÖØ´ó¿ÆÑнøÕ¹¡£Ä¿Ç°°üÀ¨¡¶ÒÅ´«¡·¡¢¡¶ÖйúÉúÎ﹤³ÌÔÓÖ¾¡·¡¢¡¶¿ÆÑ§Í¨±¨¡·µÈÖØµãÆÚ¿¯£¬Ò²»¶Ó­ÉúÎïÀàÆÚ¿¯ÁªÏµºÏ×÷£¨ÁªÏµÓÊÏ䣺[email protected]£©¡£

ѪÓѲ¡ÒÒÊÇÓÉÄýѪÒò×Ó¢ù(Factor ¢ù,F¢ù)ȱ·¦»ò¹¦ÄÜȱÏݵ¼ÖµijöѪÐÔ¼²²¡,Ϊ°éXȾɫÌåÒþÐÔÒÅ´«²¡¡£Ð¡ÊóÄ£ÐͶÔÓÚѪÓѲ¡ÒÒµÄÑо¿¾ßÓÐÊ®·ÖÖØÒªµÄÒâÒå,¶ø»ùÒò×é±à¼­¼¼ÊõÓÖΪСÊóÄ£Ð͵Ĺ¹½¨ÌṩÁËÒ»ÖÖ¿ì½Ý¶øÇÒ¸ßЧµÄ;¾¶¡£

À´×Ô¸´µ©´óѧÉúÃü¿ÆÑ§Ñ§Ôº,ÒÅ´«¹¤³Ì¹ú¼ÒÖØµãʵÑéÊҵȴ¦µÄÑо¿ÈËԱͨ¹ýCRISpR/Cas9¼¼Êõ½øÐÐF¢ù»ùÒòÇóý£¬¿ìËÙ¡¢¸ßЧµØ¹¹½¨ÑªÓѲ¡ÒÒÄ£ÐÍСÊó£¬ÒÔÆÚΪѪÓѲ¡ÒÒµÄÑо¿Ìṩ¸ü¼Ó±ã½ÝµÄ;¾¶¡£

ѪÓѲ¡ÒÒÊÇÓÉÄýѪÒò×Ó¢ù(Factor ¢ù£¬F¢ù)ȱ·¦»ò¹¦ÄÜȱÏÝËùÒýÆðµÄÒ»ÖÖ³£¼ûµÄ°éXȾɫÌåÒþÐÔÒÅ´«²¡¡£ÔÚÖйúÈËȺÖУ¬ÄÐÐԵķ¢²¡ÂÊԼΪ1/25000¡£¸Ã²¡µÄÁÙ´²ÌØÕ÷ÊÇÄýѪ¹¦ÄÜÕϰ­µ¼ÖÂ×Ô·¢³öѪ²»Ö¹£¬»òÕßÄýѪʱ¼ä¹ý³¤¡£Ä¿Ç°£¬ÖÎÁÆÑªÓѲ¡ÒÒµÄΨһÓÐЧÁÆ·¨ÎªÌæ´úÁÆ·¨£¬¼´Ê¹ÓÃŨËõѪ½¬¡¢ÖØ×éÈËÄýѪÒò×Ó¢ùÖÆ¼Á¡¢ÄýѪøԭ¸´ºÏÎï½øÐÐÊäѪÖÎÁÆ¡£

Ëæ×Ų¡¶¾Ãð»î¼¼ÊõµÄ²»¶Ï¸Ä½øºÍÖØ×éµ°°×µÄ±í´ï£¬Ìæ´úÁÆ·¨µÄ°²È«ÐԵõ½Á˱£ÕÏ¡£µ«ÓÉÓÚF¢ùµÄ°ëË¥ÆÚ¶Ì¼°·´¸´ÊäѪµ¼Ö»¼ÕßµÄѪ¹ÜÓ²»¯µÈ²¢·¢Ö¢£¬Í¬Ê±2%~4%µÄ»¼Õß»¹»á²úÉúF¢ùÒÖÖÆÎÏÞÖÆÁËÌæ´úÖÎÁƵÄÓÐЧÐÔ¡£Ö»ÓлùÒòÖÎÁƲÅÄܸùÖÎÒÅ´«²¡£¬¶øÍ¨¹ý¹¹½¨Ð¡ÊóÄ£ÐÍÀ´Ä£ÄâÈËÀ༲²¡Ò²³ÉΪÉîÈëÑо¿ºÍÄ£Äâ»ùÒòÖÎÁƵÄÓÐЧ;¾¶¡£´«Í³µÄСÊóÄ£Ð͹¹½¨¹ý³Ì·±Ëö£¬Í¨³£½«º¬ÓÐÍ»±äÐÍÄ¿µÄ»ùÒòµÄÖÊÁ£×ªÈëСÊóµÄÅßÌ¥¸Éϸ°û(Embryo stem cells£¬ES cells)ÖУ¬ÀûÓÃ×Ô·¢Í¬Ô´ÖØ×é½øÐлùÒòµÄÖû»£¬ÔÙ½«ÅßÌ¥¸Éϸ°ûÓëÊܾ«ÂÑÈںϺó½øÐд¿ºÏÍ»±äСÊóµÄɸѡ¡£¸Ã·½·¨²»½öЧÂʵͣ¬¶øÇÒɸѡ´¿ºÏСÊó¹ý³ÌºÄʱ³¤£¬Ò»°ãÐèÒª1ÄêµÄʱ¼ä²ÅÄܵõ½¼²²¡Ä£ÐÍСÊó¡£´ËÍ⣬¸Ã·½·¨ÎÞ·¨ÊµÏÖ¾«È·Î»µãµÄ¸ÄÔì¡£

¢òÐÍCRISpR/Cas9(Clustered regularly interspaced short palindromic repeat sequences/Cas9)ϵͳÊǽü¼¸Äê·¢Õ¹¼«¿ìµÄÒ»ÖÖ»ùÒò×é±à¼­¼¼Êõ¡£¸Ã¼¼ÊõÓÉÒ»Ìõ¶ÌµÄµ¥µ¼ÏòRNA(Single-guide RNA, sgRNA)Òýµ¼Cas9ºËËáøÔڰбêDNAλÖÃÉϽøÐо«È·µÄʶ±ð£¬Ôì³ÉDNA¶ÏÁѲ¢ÓÕ·¢Ï¸°ûÄÚDNAËðÉËÐÞ¸´¡£Í¨¹ý·ÇͬԴĩ¶ËÁ¬½Ó(Non-homologous end joining, NHEJ)µÄÐÞ¸´·½Ê½£¬DNA¶ÏÁÑλµã¿ÉÄܼôÇлòÕßËæ»ú²åÈëÈô¸É¼î»ù£¬´Ó¶øÔì³É¶ÏÁÑλµãµÄ»ùÒòÍ»±ä£¬´ïµ½»ùÒòÇóýµÄÄ¿µÄ£»»òÕßµ±Í¬Ô´Ä£°å´æÔÚʱ£¬Í¨¹ýÍ¬Ô´ÖØ×é(Homologous recombination, HR)µÄÐÞ¸´·½Ê½£¬¶ÔÄ¿µÄ»ùÒò½øÐмî»ùÌæ»»»òÕ߯¬¶ÎµÄ²åÈ룬ʵÏÖ¾«È·Ð޸ĻòÕß»ùÒòµÄÇÃÈë¡£CRISpR/Cas9ϵͳÖеÄsgRNAͨ¹ý¼î»ù»¥²¹Åä¶ÔÓëDNA½áºÏ£¬¾ö¶¨Á˰ÐÏòµÄ»ùÒò±à¼­µÄλÖ㬶ø¸Ãϵͳ¶Ô°ÐλµãµÄΨһҪÇóÊÇÔÚ°ÐλµãµÄ3¡ä¶ËÒª¾ßÓÐNGGÐòÁУ¬¼´pAM(protospacer adjacent motif)Çø¡£Òò´Ë¸ù¾Ý°Ðλµã¶ÔsgRNA½øÐÐÌØÒìÐÔµØÉè¼Æ£¬¾ÍÄܶԻùÒò×éÖеÄÈÎÒâλµã½øÐо«È·ÇÒ¸ßЧµØ±à¼­£¬¾ßÓкܸߵÄ×ÔÖ÷ÐÔ¡£

ÔÚÕâÆªÎÄÕÂÖУ¬Ñо¿ÈËÔ±ÀûÓÃCRISpR/Casϵͳ,ÔÚСÊóF¢ù»ùÒòµÚ8ÍâÏÔ×ÓÉÏÑ¡Ôñ°Ðλµã,½«Cas9 mRNAºÍ´øÓаÐλµãµÄsgRNAÏÔ΢עÉäµ½C57BL/6ƷϵСÊóµÄÊܾ«ÂÑÖÐ,»ñµÃ»ùÒòÐÞÊεÄСÊó¡£ÀûÓø߷ֱæÂÊÈÛ½âÇúÏß·ÖÎö(High resolution melting, HRM)¼¼Êõ½øÐо«È·»ùÒò·ÖÐÍ,²¢Í¨¹ý²âÐòÑéÖ¤,ÔÚ60ֻСÊóÖÐ,×ܹ²ÓÐ51ֻСÊóµÄ°Ðλµã·¢ÉúÁËÍ»±ä,Í»±äÂʸߴï85%,ÆäÖÐÐÛÊóµÄÍ»±äÂÊΪ79.5%,´ÆÊóµÄÍ»±äÂÊΪ95.2%;δ¼ì²âµ½·ÇÄ¿±êλÖõĻùÒò±à¼­ÍѰС£ÄýѪ»îÐÔʵÑéÏÔʾ,Í»±äСÊóµÄF¢ù»îÐÔÖµ(Factor ¢ù coagulant activity, F¢ù: C)ÊÇ·ÇÍ»±äСÊóµÄ6.82%,´ó´óµÍÓÚ·ÇÍ»±äСÊó,±íÃ÷Í»±äСÊóµÄÄýѪ»îÐÔȱʧ¡£ÕâÒ»Ñо¿±íÃ÷,ÀûÓÃCRISpR/Casϵͳ³É¹¦¹¹½¨ÁËÈËÀàѪÓѲ¡ÒÒÒÅ´«²¡Ð¡ÊóÄ£ÐÍ¡£

ÒÔÍù¹¹½¨»ùÒòȱÏÝСÊóÄ£Ð͵ķ½·¨ÊÇÔÚСÊóµÄÊܾ«ÂÑÖÐÏÔ΢עÉäÄýѪÒò×Ó¢ù´óƬ¶ÎÇóýµÄÖÊÁ££¬Í¨¹ýÍ¬Ô´ÖØ×éµÄ·½·¨À´»ñµÃ»ùÒòÇóýСÊ󣬵«ÊÇЧÂÊÖ»ÓÐ5%£¬²¢ÇÒͨ¹ý´óƬ¶ÎÇóýµ¼ÖµĻùÒòȱʧÓëÈËÀàѪÓѲ¡ÒҵĻùÒòÍ»±äÀàÐÍΪµ¥¼î»ù»òÕßСƬ¶ÎÍ»±äµÄ»ùÒòÍ»±äÀàÐͲ»Í¬£¬Òò´ËÎÞ·¨¾«È·µØÄ£ÄâÈËÀàѪÓѲ¡B¼²²¡µÄ»ùÒòÐÍ¡£

ÕâÏîÑо¿ÀûÓÃCRISpR/Cas9ϵͳÄܹ»¸ßЧµØ½«ÌØÒìÐÔ°ÐλµãµÄDNAË«Á´´ò¶Ï£¬Í¨¹ýNHEJÐÞ¸´·½Ê½£¬ÔÚ¶ÏÁÑ´¦Ëæ»úÒýÈë¼î»ùµÄȱʧ»òÕß²åÈ룬ʹ»ùÒò²úÉúÒÆÂëÍ»±ä¡£µ«ÎªÁ˸üºÃµØÄ£ÄâÔÚÍâÏÔ×ÓÐòÁÐÖÐÓÉ´íÒåÍ»±äÒýÆðµÄÈËÀàÒÅ´«¼²²¡£¬ÀýÈç´ó²¿·ÖÈËÀàѪÓѲ¡BµÄ»ùÒòÐÍ£¬ÀíÂÛÉÏ¿ÉÒÔÏÔ΢¹²×¢ÉäDNAͬԴģ°å£¬¼´ÀûÓÃHR·½·¨£¬¸ü¼Ó¾«È·µØ¹¹½¨Ìض¨»ùÒòÐ͵ÄСÊóÄ£ÐÍ¡£¶Ô»ùÒòÖÎÁÆÀ´Ëµ£¬Í¬ÑùÒ²ÊÇÀûÓÃHRµÄÐÞ¸´·½Ê½£¬½«´íÎóµÄÐòÁÐÌæ»»ÎªÕý³£ÐòÁС£

ÕâÆªÎÄÕÂÒ²³É¹¦µØ¶ÔѪÓѲ¡ÒÒСÊóÔÚÊܾ«ÂÑˮƽÉϽøÐÐÁ˳õ²½µÄ»ùÒò¾ÀÕý¡£µ«ÊÇ£¬Ä¿Ç°HRµÄÐÞ¸´·½Ê½Ïà±ÈNHEJµÄÐÞ¸´·½Ê½Ð§ÂÊÒªµÍ£¬Òò´Ë¶ÔÓÚÈçºÎÌá¸ßHRµÄЧÂÊÑо¿Ò²¾ßÓÐÊ®·ÖÖØÒªµÄÒâÒå¡£ÁíÍ⣬ÔÚCRISpR/Cas9ϵͳӦÓÃÖÐÍѰÐЧӦÊÇÈËÃÇËù¹Ø×¢µÄÖØµãÖ®Ò»¡£ÑÐ
¾¿·¢ÏÖͨ¹ý¶ÔCas9ºËËáøµ°°×µÄÇиîÓò½øÐÐÍ»±ä£¬ÀûÓÃÐÞÊÎÐ͵ÄCas9ºËËáø¿ÉÒÔʹDNAË«Á´µÄÆäÖÐÒ»ÌõÁ´¶ÏÁÑ£¬´Ó¶ø´ó´ó½µµÍÍѰÐЧӦµÄ²úÉú¡£

Ñо¿Í¨¹ýCRISpR/Cas9ϵͳ³É¹¦¹¹½¨ÁËѪÓѲ¡ÒÒСÊóÄ£ÐÍ£¬Î´À´½«»áÀûÓÃCRISpR/Cas9ϵͳ¹¹½¨¾«È·¼î»ùÐ޸ĵÄÍ»±äÀàÐ͵ÄѪÓѲ¡ÒÒСÊóÄ£ÐÍ£¬ÒÔ¼°ÀûÓÃCRISpR/Cas9ϵͳÔÚÉúֳϸ°ûºÍÌåϸ°ûˮƽ¶ÔËù¹¹½¨µÄѪÓѲ¡ÒÒСÊó½øÐлùÒòÐÞ¸´¡£

£¨ÉúÎïͨ£©

ϵÁÐÎÄÕ£º

ÔËÓÃCRISpR¼¼Êõ¹¹½¨CTCFµ°°×½µ½âϸ°ûϵ

»ùÓÚCRISpR-Cas9ϵͳ¸ßͨÁ¿É¸Ñ¡Ñо¿¹¦ÄÜ»ùÒò

CRISpR/Cas9¼¼Êõ¼°ÆäÔÚת»ùÒò¶¯ÎïÖеÄÓ¦ÓÃ

CRISpR/Cas9ϵͳÖÐsgRNAÉè¼ÆÓëÍѰÐЧӦÆÀ¹À

CRISpR/Cas9»ùÒò×é±à¼­¼¼ÊõÔÚHIV-1¸ÐȾÖÎÁÆÖеÄÓ¦ÓýøÕ¹

CRISpR/Cas9»ùÒò×é±à¼­¼¼ÊõÔÚ°©Ö¢Ñо¿ÖеÄÓ¦ÓÃ

Ô­ÎļìË÷£º

ÍôÆôº²,»³´Ï,ËïÈðÁÖ,ׯ»ª,³ÂºìÑÒ,·Ñ¼ó,¬´óÈå. ÀûÓÃCRISpR/Casϵͳ¿ìËÙ¸ßЧ¹¹½¨ÑªÓѲ¡ÒÒСÊóÄ£ÐÍ[J]. ÒÅ´«, 2015, 37(11): 1143-1148.
Qihan Wang,Cong Huai,Ruilin Sun,Hua Zhuang,Hongyan Chen,Jian Fei,Daru Lu. A quick and efficient method to generate hemophilia B mouse models by the CRISpR/Cas system. HEREDITAS(Beijing), 2015, 37(11): 1143-1148.